跳至主要内容
临床试验/NL-OMON20556
NL-OMON20556招募中不适用

Concentration-guided dose reduction versus standard dosing in tocilizumab-treated rheumatoid arthritis patients: a randomised, multicenter, non-inferiority trial

Reade Rheumatology Research Institute0 个研究点目标入组 98 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
98

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Rheumatoid arthritis according to the American College of Rheumatology (ACR) 1987 or 2010 criteria;
  • - Current use of subcutaneous tocilizumab 162 mg weekly, for at leas the previous 6 months;
  • - The treating rheumatologist is convinced of the benefit of tocilizumab continuation;
  • - Written informed consent.

排除标准

  • - A scheduled surgery in the next 52 weeks or other pre-planned reasons for treatment discontinuation;
  • - Changes in the treatment with glucocorticoids or DMARDs such as methotrexate in the past three months.

研究者

发起方
Reade Rheumatology Research Institute

相似试验